514 related articles for article (PubMed ID: 16928813)
1. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
3. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
4. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization.
Reinhardt HC; Hasskamp P; Schmedding I; Morandell S; van Vugt MA; Wang X; Linding R; Ong SE; Weaver D; Carr SA; Yaffe MB
Mol Cell; 2010 Oct; 40(1):34-49. PubMed ID: 20932473
[TBL] [Abstract][Full Text] [Related]
5. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Demidova AR; Aau MY; Zhuang L; Yu Q
J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
[TBL] [Abstract][Full Text] [Related]
6. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
Reinhardt HC; Aslanian AS; Lees JA; Yaffe MB
Cancer Cell; 2007 Feb; 11(2):175-89. PubMed ID: 17292828
[TBL] [Abstract][Full Text] [Related]
7. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
Zhang WH; Poh A; Fanous AA; Eastman A
Cell Cycle; 2008 Jun; 7(11):1668-77. PubMed ID: 18469532
[TBL] [Abstract][Full Text] [Related]
8. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
10. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.
Carrassa L; Broggini M; Erba E; Damia G
Cell Cycle; 2004 Sep; 3(9):1177-81. PubMed ID: 15326376
[TBL] [Abstract][Full Text] [Related]
11. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.
Xiao Z; Chen Z; Gunasekera AH; Sowin TJ; Rosenberg SH; Fesik S; Zhang H
J Biol Chem; 2003 Jun; 278(24):21767-73. PubMed ID: 12676925
[TBL] [Abstract][Full Text] [Related]
12. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.
Huang M; Miao ZH; Zhu H; Cai YJ; Lu W; Ding J
Mol Cancer Ther; 2008 Jun; 7(6):1440-9. PubMed ID: 18566216
[TBL] [Abstract][Full Text] [Related]
13. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
[TBL] [Abstract][Full Text] [Related]
14. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
15. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.
Reinhardt HC; Yaffe MB
Curr Opin Cell Biol; 2009 Apr; 21(2):245-55. PubMed ID: 19230643
[TBL] [Abstract][Full Text] [Related]
16. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
Jin J; Ang XL; Ye X; Livingstone M; Harper JW
J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Agner J; Falck J; Lukas J; Bartek J
Exp Cell Res; 2005 Jan; 302(2):162-9. PubMed ID: 15561098
[TBL] [Abstract][Full Text] [Related]
18. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
[TBL] [Abstract][Full Text] [Related]
19. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
[TBL] [Abstract][Full Text] [Related]
20. Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation.
Ye F; Yang Z; Liu Y; Gong D; Ji T; Wang J; Xi B; Zhou J; Ma D; Gao Q
Cancer Gene Ther; 2014 May; 21(5):209-17. PubMed ID: 24853623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
